Kyujin Hwang

Kyujin Hwang

Auto-generated profile, based on publicly available information

Kyujin Hwang

Brain Korea 21 Plus Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2015 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
ILIl-Shin Lee
Il-Shin Lee
KJKwangsoo Jung
Kwangsoo Jung
IKIl-Sun Kim
Il-Sun Kim
HLHaejin Lee
Haejin Lee
MKMiri Kim
Miri Kim
KPKook In Park
Kook In Park
Alzheimer’s disease (AD) is an inexorable neurodegenerative disease that commonly occurs in the elderly. The cognitive impairment caused by AD is associated with abnormal accumulation of amyloid-β (Aβ) and hyperphosphorylated tau, which are accompanied by inflammation. Neural stem cells (NSCs) are self-renewing, multipotential cells that differentiate into distinct neural cells. When transplanted into a diseased brain, NSCs repair and replace injured tissues after migration toward and engraftment within lesions. We investigated the therapeutic effects in an AD mouse model of human NSCs (hNSCs) that derived from an aborted human fetal telencephalon at 13 weeks of gestation. Cells were transplanted into the cerebral lateral ventricles of neuron-specific enolase promoter-controlled APPsw-expressing (NSE/APPsw) transgenic mice at 13 months of age. Implanted cells extensively migrated and engrafted, and some differentiated into neuronal and glial cells, although most hNSCs remained immature. The hNSC transplantation improved spatial memory in these mice, which also showed decreased tau phosphorylation and Aβ42 levels and attenuated microgliosis and astrogliosis. The hNSC transplantation reduced tau phosphorylation via Trk-dependent Akt/GSK3β signaling, down-regulated Aβ production through an Akt/GSK3β signaling-mediated decrease in BACE1, and decreased expression of inflammatory mediators through deactivation of microglia that was mediated by cell-to-cell contact, secretion of anti-inflammatory factors generated from hNSCs, or both. The hNSC transplantation also facilitated synaptic plasticity and anti-apoptotic function via trophic supplies. Furthermore, the safety and feasibility of hNSC transplantation are supported. These findings demonstrate the hNSC transplantation modulates diverse AD pathologies and rescue impaired memory via multiple mechanisms in an AD model. Thus, our data provide tangible preclinical evidence that human NSC transplantation could be a safe and versatile approach for treating AD patients.

11 October 2015 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
JSJi Cheol Shin
Ji Cheol Shin
KKKeung Nyun Kim
Keung Nyun Kim
JYJeehyun Yoo
Jeehyun Yoo
IKIl-Sun Kim
Il-Sun Kim
SYSeokhwan Yun
Seokhwan Yun
KPKook In Park
Kook In Park
In a phase I/IIa open-label and nonrandomized controlled clinical trial, we sought to assess the safety and neurological effects of human neural stem/progenitor cells (hNSPCs) transplanted into the injured cord after traumatic cervical spinal cord injury (SCI). Of 19 treated subjects, 17 were sensorimotor complete and 2 were motor complete and sensory incomplete. hNSPCs derived from the fetal telencephalon were grown as neurospheres and transplanted into the cord. In the control group, who did not receive cell implantation but were otherwise closely matched with the transplantation group, 15 patients with traumatic cervical SCI were included. At 1 year after cell transplantation, there was no evidence of cord damage, syrinx or tumor formation, neurological deterioration, and exacerbating neuropathic pain or spasticity. The American Spinal Injury Association Impairment Scale (AIS) grade improved in 5 of 19 transplanted patients, 2 (A → C), 1 (A → B), and 2 (B → D), whereas only one patient in the control group showed improvement (A → B). Improvements included increased motor scores, recovery of motor levels, and responses to electrophysiological studies in the transplantation group. Therefore, the transplantation of hNSPCs into cervical SCI is safe and well-tolerated and is of modest neurological benefit up to 1 year after transplants. This trial is registered with Clinical Research Information Service (CRIS), Registration Number:KCT0000879.

20 April 2018 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
JSJeong Eun Shin
Jeong Eun Shin
KJKwangsoo Jung
Kwangsoo Jung
MKMiri Kim
Miri Kim
KHKyujin Hwang
Kyujin Hwang
HLHaejin Lee
Haejin Lee
KPKook In Park
Kook In Park
Hypoxic-ischemic (HI) brain injury and spinal cord injury (SCI) lead to extensive tissue loss and axonal degeneration. The combined application of the polymer scaffold and neural progenitor cells (NPCs) has been reported to enhance neural repair, protection and regeneration through multiple modes of action following neural injury. This study investigated the reparative ability and therapeutic potentials of biological bridges composed of human fetal brain-derived NPCs seeded upon poly(glycolic acid)-based scaffold implanted into the infarction cavity of a neonatal HI brain injury or the hemisection cavity in an adult SCI. Implantation of human NPC (hNPC)–scaffold complex reduced the lesion volume, induced survival, engraftment, and differentiation of grafted cells, increased neovascularization, inhibited glial scar formation, altered the microglial/macrophage response, promoted neurite outgrowth and axonal extension within the lesion site, and facilitated the connection of damaged neural circuits. Tract tracing demonstrated that hNPC–scaffold grafts appear to reform the connections between neurons and their targets in both cerebral hemispheres in HI brain injury and protect some injured corticospinal fibers in SCI. Finally, the hNPC–scaffold complex grafts significantly improved motosensory function and attenuated neuropathic pain over that of the controls. These findings suggest that, with further investigation, this optimized multidisciplinary approach of combining hNPCs with biomaterial scaffolds provides a more versatile treatment for brain injury and SCI.

23 October 2015 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
JKJeong Beom Kim
Jeong Beom Kim
HLHyunah Lee
Hyunah Lee
MAMarcos J. Araúzo-Bravo
Marcos J. Araúzo-Bravo
KHKyujin Hwang
Kyujin Hwang
DNDonggyu Nam
Donggyu Nam
SLSeok‐Jin Lee
Seok‐Jin Lee

31 December 2019 in Experimental Neurobiology
Verified
Journal Article
Open access
PDF file
KHKyujin Hwang
Kyujin Hwang
KJKwangsoo Jung
Kwangsoo Jung
IKIl-Sun Kim
Il-Sun Kim
MKMiri Kim
Miri Kim
JHJungho Han
Jungho Han
KPKook In Park
Kook In Park
Kyujin Hwang, Kwangsoo Jung, Il-Sun Kim, Miri Kim, Jungho Han, Joohee Lim, Jeong Eun Shin, Jae-Hyung Jang and Kook In Park. Exp Neurobiol 2019;28:679-96. https://doi.org/10.5607/en.2019.28.6.679

11 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
MKMiri Kim
Miri Kim
KJKwangsoo Jung
Kwangsoo Jung
YKYounhee Ko
Younhee Ko
IKIl-Sun Kim
Il-Sun Kim
KHKyujin Hwang
Kyujin Hwang
KPKook In Park
Kook In Park
Neural progenitor cells (NPCs) therapy offers great promise in hypoxic-ischemic (HI) brain injury. However, the poor survival of implanted NPCs in the HI host environment limits their therapeutic effects. Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine that is induced in response to a variety of pathological processes including inflammation and immunity. On the other hand, TNF-α has protective effects on cell apoptosis and death and affects the differentiation, proliferation, and survival of neural stem/progenitor cells in the brain. The present study investigated whether TNF-α pretreatment on human NPCs (hNPCs) enhances the effectiveness of cell transplantation therapy under ischemic brain. Fetal brain tissue-derived hNPCs were pretreated with TNF-α before being used in vitro experiments or transplantation. TNF-α significantly increased expression of cIAP2, and the use of short hairpin RNA-mediated knockdown of cIAP2 demonstrated that cIAP2 protected hNPCs against HI-induced cytotoxicity. In addition, pretreatment of hNPCs with TNF-α mediated neuroprotection by altering microglia polarization via increased expression of CX3CL1 and by enhancing expression of neurotrophic factors. Furthermore, transplantation of TNF-α-treated hNPCs reduced infarct volume and improved neurological functions in comparison with non-pretreated hNPCs or vehicle. These findings show that TNF-α pretreatment, which protects hNPCs from HI-injured brain-induced apoptosis and increases neuroprotection, is a simple and safe approach to improve the survival of transplanted hNPCs and the therapeutic efficacy of hNPCs in HI brain injury.